Trial Profile
Phase II study of neoadjuvant S-1 concurrent radiotherapy for borderline resectable pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Ductal carcinoma; Pancreatic cancer; Squamous cell cancer
- Focus Therapeutic Use
- 24 Oct 2022 Results published in the Annals of Surgery.
- 04 Jun 2019 Results assessing final results of a phase II trial of neoadjuvant S-1 and radiotherapy in resectable pancreatic cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Status changed from active, no longer recruiting to completed.